iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

Ads

You May Also Like

Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

Orion Corporation                                                                            Press ReleaseCommunications                                                                              14 February 2019 at 11.45 p.m. EET Orion's and ...

ADMA Biologics to Present at Upcoming Investor Conferences

RAMSEY, N.J., Aug. 23, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or ...